Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of LP002 plus carboplatin and etoposide as first-line treatment for extensive-stage small cell lung cancer
CTR20201477Phase 2Completed
- Sponsor
- Taizhou Houde Aoke Technology
- Start
- Dec 2020
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LP002 in small cell lung cancer (SCLC), sponsored by Taizhou Houde Aoke Technology. Started Dec 2020; status: completed.
02
Drugs
LP002
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20201477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201477.